MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression

MEK inhibitors (MEKi) have limited efficacy in KRAS mutant lung adenocarcinoma (LUAD) patients, and this is attributed to both intrinsic and adaptive mechanisms of drug resistance. While many studies have focused on the former, there remains a dearth of data regarding acquired resistance to MEKi in...

Descripción completa

Detalles Bibliográficos
Autores principales: Farnsworth, Dylan A., Inoue, Yusuke, Johnson, Fraser D., de Rappard-Yuswack, Georgia, Lu, Daniel, Shi, Rocky, Ma, Lok In Josephine, Mattar, Marissa S., Somwar, Romel, Ladanyi, Marc, Unni, Arun M., Lockwood, William W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684561/
https://www.ncbi.nlm.nih.gov/pubmed/36418460
http://dx.doi.org/10.1038/s41698-022-00328-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684561/
https://www.ncbi.nlm.nih.gov/pubmed/36418460
http://dx.doi.org/10.1038/s41698-022-00328-x

Ejemplares similares